Gyre Therapeutics, Inc. Share Price
GYREGyre Therapeutics, Inc. Stock Performance
Open $7.49 | Prev. Close $7.37 | Circuit Range N/A |
Day Range $7.49 - $7.70 | Year Range $6.61 - $11.78 | Volume 2,436 |
Average Traded $7.63 |
Gyre Therapeutics, Inc. Share Price Chart
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $7.49 | $7.65 | +0.00% |
30-Apr-26 | $7.49 | $7.65 | -0.39% |
28-Apr-26 | $7.66 | $7.68 | +0.39% |
27-Apr-26 | $7.55 | $7.65 | +2.55% |
24-Apr-26 | $7.45 | $7.46 | -3.56% |
22-Apr-26 | $7.83 | $7.74 | -1.72% |
21-Apr-26 | $7.93 | $7.87 | -0.88% |
FAQs on Gyre Therapeutics, Inc. Share Price
Can I buy Gyre Therapeutics, Inc. shares in India?
What is the share price of Gyre Therapeutics, Inc.?
What is the 5 year returns of Gyre Therapeutics, Inc.?
What are the high & low stock price of Gyre Therapeutics, Inc. today?
What is the 52-week high and low of Gyre Therapeutics, Inc. stock?